BillionToOne

Founded in 2016 by Dave Tsao, Oguzhan Atay, and Sukrit Silas, BillionToOne is a DNA diagnostic company originating from Y Combinator's S17 accelerator batch. It is located in Palo Alto, California, and uses diagnostic DNA testing that quantifies molecular level bodily changes.

COVID-19 Response

BillionToOne received emergency use authorization from the Food and Drug Administration (FDA) in 2020, for its SARS-CoV-2 test that removes the process of Ribo Nucleic Acid (RNA) extraction, a time-consuming step in COVID-19 testing. BillionToOne developed a COVID-19 testing method called the qSanger-COVID-19 assay. It uses different instrument sets and chemicals than other methods that were applied in 2020. BillionToOne partnered with SwiftBiosciences to manufacture the COVID-19 assay kits and began international distribution in May of 2020.

qSanger

qSanger^TM technology is a patent-pending test developed by BillionToOne that works to detect viral RNA. It is based on the technology in Sanger sequencing, a DNA testing method that determines the nucleotide sequence in DNA molecules, also known as the "chain termination method."

Timeline

March 2020

BillionToOne raises a $15,000,000 series A round from NeoTribe Ventures, Y Combinator, HOF Capital, Friále, Civilization Ventures, 500 Startups Istanbul, Hummingbird Ventures and Libertus Capital.

March 13, 2019

BillionToOne raises a $15,000,000 series A round from NeoTribe Ventures, Y Combinator, 500 Startups, Fifty Years, HOF Capital, Civilization Ventures and Hummingbird Ventures.

September 15, 2017

BillionToOne raises a $2,400,000 seed round from Friále, Wei Guo, NewDo Venture and UpHonest Capital.

August 2017

BillionToOne raises a $120,000 seed round from Y Combinator.

January 2016

BillionToOne was founded by Dave Tsao, Oguzhan Atay and Sukrit Silas.